N/A N=106 Hepatic Effects of Gastric Bypass Surgery
Liver Diseases
Primary: Aspartate Transaminase (AST) Change — -6.32 U/L — p=0.03
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 Chronic Liver Disease in Urea Cycle Disorders
Urea Cycle Disorder
Primary: Liver Stiffness as Measured by Shear Wave Elastography — 13; 14 Participants
Phase 2 N=80 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis
Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change
N/A N=14 Team Science (The Liver Health Study)
Steatotic Liver Disease of Mixed Origin (MetALD)
Primary: Proportion Screened With Alcohol Intake and Weight-related Risks for Metabolism and Alcohol-associated Liver Disease — 26 Participants
N/A N=1,061 Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
Fatty Liver, Nonalcoholic · Diabetes Mellitus, Type 2
Primary: Action on Suspected Advanced Liver Fibrosis — 55; 4 Participants
N/A N=5 Adult Stem Cell Therapy in Liver Insufficiency
Liver Cirrhosis
Primary: Number of Participants With Serious Adverse Events Related to Injection — 0 Participants
Phase 2 N=12 The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
NAFLD · Nonalcoholic Fatty Liver · NASH - Nonalcoholic Steatohepatitis
Primary: Intrahepatic Lipid Content (IHL, Percent Liver Fat) — 3.9 absolute change in percentage liver fat — p=0.4
N/A N=51 Obesity and Nonalcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Hepatic Insulin Sensitivity Index (HISI) — 0.8; 1.4 [10000/(μmol/min)x(mU/L)] — p=<0.019
Phase 4 N=276 Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
Chronic Liver Disease
Primary: PV Flow — 16.0; 15.5; 23.2; 27.1 ml/s
N/A N=2,600 Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Liver Failure, Acute on Chronic
Primary: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate — 74; 124; 74 Participants
Phase 2 N=53 Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Change in Intrahepatic Lipid Content Between Baseline and 6 Months as Measured by 1H-magnetic Resonance Spectroscopy (1H-MRS). Endpoints Were Assessed at Baseline and 6…
Phase 1 N=35 A Single Dose Study of LY2605541 in Participants With Liver Impairment
Healthy Volunteers · Hepatic Insufficiency · Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY2605541 — 85200; 67200; 64300; 66600 picomole*hours/liter (pmol*h/L)
Phase 4 N=10 The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
Chronic Hepatitis · Chronic Hepatitis C · Chronic Alcoholic Hepatitis
Primary: The Change in Serum Alanine Aminotransferase Level From Baseline to 12 Weeks — 77.5; 105.5 IU/L
N/A N=67 Liver Cancer Community Education
Liver Cancer
Primary: Change in Mean Liver Cancer Knowledge — 1.26 score on a scale
N/A N=3,800 Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs
Cancer
Primary: Number of Patients With ALT (Alanine Transaminase) >=3x (Times) Upper Limit of Normal (ULN) — 11 participants
Phase 2 N=78 Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis
Non-alcoholic Steatohepatitis
Primary: Efficacy - Improvement by at Least 2 Points in Histology (NAS) — 5; 4; 3 participants
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 2 N=5 A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency
Liver Disease
Primary: Number of Patients Who Tolerated the Maximum Dose — 5 Participants
Phase 2 N=25 Anti-LPS Antibody Treatment for Pediatric NAFLD
Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Percent Change in Alanine Aminotransferase (ALT) Level — 11.99; -7.99 percentage change
N/A N=84 Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications
Fatty Liver · Surgery
Primary: Percentage of Liver Fat Content on MRI in Patients With Serious Post-operative Complications (Clavien-Dindo Grade ≥IV) — 1.3; 13.6 Percentage of liver fat content
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
N/A N=104 Investigation of Synbiotic Treatment in NAFLD
Non-Alcoholic Fatty Liver Disease
Primary: Change in Liver Fat — -3.8; -6.0 percentage of liver fat — p==0.05
Phase 3 N=91 Effects of SAMe in Patients With Alcoholic Liver Disease
Liver Disease, Alcoholic
Primary: Changes in Serum AST Levels — -13.5; -56 Units per liter (U/L)
N/A N=8 Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
Non-Alcoholic Fatty Liver Disease
Primary: Participants With Normalized Liver Enzyme Levels — 0; 0 Participants
Phase 2 N=155 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
Hepatic Cirrhosis · Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 — 28.2; 24.3; 28.2…
Phase 4 N=130 Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
Alcoholic Liver Disease
Primary: Liver Enzymes(ALT) — 66; 48 IU/L
Phase 2 N=25 Human Fetal Liver Cell Transplantation in Chronic Liver Failure
Liver Cirrhosis
Primary: Patient Survival — 5; 6; 4; 10 participants — p=0.4340
Phase 2 N=86 A Study of IDN-6556 in Subjects With Liver Cirrhosis
Liver Cirrhosis · Hepatic Cirrhosis
Primary: Change From Baseline at Month 3 in cCK18/M30 — 293.5; 257.5; 288.5; 285.0 U/L
N/A N=50 Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom
Candidiasis
Primary: Percentage of Participants With Favorable Outcome — 76.1 percentage of participants
Phase 1 N=2 Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis
Hepatitis C · Liver Cirrhosis
Primary: AUC 0-∞ — 7240; 24700 h*ng/mL